期刊文献+

支气管扩张症患者感染多重耐药铜绿假单胞菌的影响因素分析 被引量:6

Risk factors for infection of multi-drug resistant Pseudomonas aeruginosa in patients with bron-chiectasis
下载PDF
导出
摘要 目的探讨支气管扩张症患者感染多重耐药铜绿假单胞菌(MDRP)的影响因素,为临床合理应用抗菌药物、减少多重耐药菌的产生提供科学依据。方法回顾性分析因支气管扩张症伴感染导致住院且痰培养分离出铜绿假单胞菌(PA)的患者病历资料,依据药物敏感试验结果分为MDRP组与非MDRP组,采用t检验、χ2检验和Wilcoxon秩和检验对临床资料进行初筛,再行Logistic逐步回归分析,探讨MDRP感染的影响因素。结果共纳入98株PA,其中MDRP组34株,非MDRP组64株,经统计分析,近1年住院次数(OR=2.419,95%CI 1.559~3.752,P<0.001)、ICU/呼吸重症监护病房(RICU)入住史(OR=4.486,95%CI 1.290~15.602,P=0.018)、咯血(OR=4.702,95%CI 1.110~19.918,P=0.036)是MDRP感染的影响因素。结论近1年频繁住院、ICU/RICU入住史、咯血是MDRP感染的重要危险因素。 Objective To explore the risk factors for the infection of multi-drug resistant Pseudomonas aeruginosa(MDRP)in patients with bronchiectasis,and to provide scientific basis for the rational application of antimicrobial agents and the reduction of multi-drug resistant bacteria(MDROs).Method Retrospective analysis was performed on the data of patients who hospitalized with bronchiectasis associated with infection and isolated Pseudomonas aeruginosa(PA)from sputum culture.These cases were divided into MDRP group and non-MDRP group according to drug sensitivity results.Student’s-test,Chisquare test or Wilcoxon rank sum test was used to screen the clinical data,and then Logistic stepwise regression analysis was performed to explore the independent risk factors for MDRP infection.Results A total of 98 PA strains were collected,including 34 in the MDRP group and 64 in the non-MDRP group.Statistical analysis showed that hospitalization frequency in the recent one year(OR=2.419,95%CI 1.559-3.752,P<0.001),ICU/RICU hospitalization history(OR=4.486,95%CI 1.290-15.602,P=0.018),hemoptysis(OR=4.702,95%CI 1.110-19.918,P=0.036)were independent risk factors for MDRP infection.Conclusion Frequent hospitalization in the recent one year,ICU/RICU hospitalization history,hemoptysis are important risk factors for MDRP infection,and identification of these characteristics is beneficial to the prevention and treatment of MDRP.
作者 彭连军 王红嫚 李有霞 范绍辉 阳曼丽 Peng Lianjun;Wang Hongman;Li Youxia;Fan Shaohui;Yang Manli(Department of Respiratory and Critical Care Medicine,the Fifth Affiliated Hospital of Zunyi Medical University,Zhuhai 519100,China)
出处 《新医学》 CAS 2021年第6期432-436,共5页 Journal of New Medicine
基金 贵州省卫生计生委科学技术基金项目(gzwjkj2015-1-046) 遵义医科大学第二批重点扶持学科建设项目。
关键词 支气管扩张症 铜绿假单胞菌 多重耐药菌 耐药性 Bronchiectasis Pseudomonas aeruginosa Multi-drug resistant bacteria Drug resistance
  • 相关文献

参考文献8

二级参考文献56

  • 1章瑞云,钱小毛.铜绿假单胞菌在重症监护病房流行及控制措施[J].中华医院感染学杂志,2007,17(3):269-271. 被引量:31
  • 2牛秀明,官波.铜绿假单胞菌的耐药性及碳青霉烯类抗生素的研究进展[J].国外医学(药学分册),2007,34(3):194-199. 被引量:6
  • 3陈新谦 金有豫 汤光.新编药物学[M]15版[M].北京:人民卫生出版社,2003.583.
  • 4Zhong N, Wang C, Yao W, et al. Prevalence of chronicobstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med,2007 ,176 :753-760.
  • 5Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest,2010,138:944-949.
  • 6Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med,2010,104:981-985.
  • 7Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis " too high" for a developed country. Arch Dis Child,2005,90:737-740.
  • 8Barker AF. Bronchiectasis. N Engl J Med,2002 ,346 :1383-1393.
  • 9Kim C, Kim DG. Bronchiectasis. Tuberc Respir Dis ( Seoul ), 2012,73:249-257.
  • 10Hill AT, Pasteur M, Cornford C, et al. Primary care summary of the British Thoracic Society Guideline on the management of non- cystic fibrosis bronchieetasis. Prim Care Respir J, 2011,20 : 135- 140.

共引文献215

同被引文献57

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部